Core Insights - Femasys Inc. has appointed Dr. Kenneth D. Eichenbaum to its Board of Directors, bringing over 20 years of experience in evaluating biotechnology and medical device companies [1][2] - Dr. Eichenbaum's clinical and financial expertise is expected to enhance Femasys' strategic direction as the company continues to innovate in women's health [2] - The company is focused on making fertility and non-surgical permanent birth control more accessible and cost-effective through its patented products [3] Company Overview - Femasys is a biomedical innovator with a portfolio of therapeutic and diagnostic products aimed at improving women's reproductive health [3] - The company's lead products include FemaSeed, FemSperm, and FemVue, with FemaSeed demonstrating more than double the pregnancy rates of traditional IUI [3] - FemBloc, a non-surgical permanent birth control method, received regulatory approval in Europe, the UK, and New Zealand, and is set for commercialization through strategic partnerships [4] Product Innovations - FemaSeed is a groundbreaking infertility treatment, while FemSperm is a sperm preparation and analysis product line [3] - FemBloc is the first non-surgical alternative to surgical sterilization, with initial clinical trials showing compelling effectiveness and high satisfaction rates [4] - The FemChec diagnostic product provides an ultrasound-based test to confirm procedural success, further enhancing the patient experience [4]

Core Viewpoint - Femasys Inc. has granted stock options to two new non-executive employees as part of their employment inducement strategy, reflecting the company's commitment to expanding its workforce and enhancing its innovative capabilities in the biomedical sector [1][2]. Company Overview - Femasys is a biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women globally through a broad, patent-protected portfolio of therapeutic and diagnostic products [3]. - The company is actively commercializing its lead product innovations in the U.S. and key international markets, with a focus on enhancing fertility treatment options and permanent birth control solutions [3]. Product Innovations - Femasys' fertility portfolio includes: - FemaSeed Intratubal Insemination (ITI), which has demonstrated more than double the pregnancy rates of traditional IUI with a comparable safety profile [3]. - FemSperm, a sperm preparation and analysis product line [3]. - FemVue, a companion diagnostic for fallopian tube assessment [3]. - FemBloc is the first and only non-surgical, in-office alternative to surgical sterilization, receiving full regulatory approval in Europe, the UK, and New Zealand in 2025 [4]. - The FemChec diagnostic product provides an ultrasound-based test to confirm procedural success, with initial clinical trials showing compelling effectiveness and high satisfaction rates [4]. Stock Options and Employment Strategy - Femasys granted options to purchase 185,000 shares at exercise prices of $0.50 and $0.57, equal to the closing stock price on the employment date [2]. - The stock options will vest 25% on the first anniversary of employment, with the remaining shares vesting 25% each year over the next three years, contingent on continued employment [2].

Core Insights - Femasys Inc. has announced that its FemBloc permanent birth control system has achieved MDSAP certification, which will facilitate regulatory and commercial execution in key global markets [1][2] - The MDSAP certification enhances the company's manufacturing credibility and operational scalability, supporting ongoing commercialization in Europe and enabling market entry in additional high-value regions [1][2] Company Overview - Femasys is a biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women globally through a patent-protected portfolio of products [3] - The company is actively commercializing its lead product innovations in the U.S. and key international markets, including a fertility portfolio that features FemaSeed, FemSperm, and FemVue [3] Product Details - FemBloc is a non-surgical solution for permanent birth control that addresses the unmet need in women's reproductive health by using a patented delivery system to create natural scar tissue for permanent occlusion [2][4] - The product has received full regulatory approval in Europe, the UK, and New Zealand, and its commercialization will be completed through strategic partnerships in select European countries [4]